One-year trial results show most patients kept off GLP-1-induced weight loss after a single endoscopic procedure.
GLP-1 drugs have transformed obesity treatment, but they have also created a new clinical problem: what happens when patients stop taking them. Weight regain after discontinuation is common and well documented, and it has opened a commercial opportunity for therapies designed to lock in GLP-1-driven weight loss without ongoing drug therapy.
Fractyl Health’s second-quarter results, released last month, offer the clearest one-year data yet on whether its procedural therapy, Revita, can do exactly that [1].
The company’s REMAIN-1 programme is structured around three cohorts studied under a single investigational device exemption: the open-label REVEAL-1 Cohort, the randomized REMAIN-1 Midpoint Cohort, and the REMAIN-1 Pivotal Cohort, whose topline data are still to come.
In the REVEAL-1 Cohort, 15 participants who underwent a single Revita procedure after GLP-1 discontinuation showed a mean total body weight change of 5.3% at one year, equivalent to maintaining roughly 78% of their prior GLP-1-induced weight loss. That is real-world, open-label evidence, useful but not the gold standard.
The more rigorous signal comes from the randomized REMAIN-1 Midpoint Cohort. In a pre-specified optimized subgroup, patients who received complete duodenal ablation (greater than 14cm) combined with higher GLP-1-induced weight loss during the run-in period (17.5% or more), Revita-treated participants maintained approximately 84% of their GLP-1-induced weight loss at one year, against 46% in the sham-treated group.
In absolute terms, that translates to a least-squares mean weight regain of 4.1% for Revita patients versus 13.5% for sham, in a small but randomized and controlled comparison of 10 versus 8 participants. Fractyl reported no device- or procedure-related serious adverse events through one year, and no new device-related treatment-emergent adverse events between six and twelve months.
Reading the data with appropriate caution
The optimized-subgroup result is the headline figure, but it is worth being precise about what it represents. It reflects a small, pre-specified subgroup selected for having received a more complete procedural dose and a stronger initial GLP-1 response, not the trial’s full randomized population.
Fractyl positions this as directionally informative for the REMAIN-1 Pivotal Cohort, whose six-month topline randomized readout is expected in early Q4 2026, but the pivotal data will be the real test of whether the effect holds at scale and across a broader, less selected patient group.
The financial picture
Fractyl’s second-quarter results show a company managing its cash runway carefully as it approaches these pivotal milestones. Research and development spending fell to $13.8 million for the quarter, down from $21.2 million a year earlier, while SG&A rose modestly to $5.3 million on higher stock compensation costs. Net loss narrowed to $25.5 million from $27.9 million, and adjusted EBITDA loss improved to $16.3 million from $24.0 million.
The company held approximately $47.1 million in cash and cash equivalents as of 30 June, which management says will fund operations into early 2027, beyond the anticipated pivotal data readout and a potential FDA De Novo submission.
That submission timeline is itself a milestone worth watching. Fractyl expects topline six-month Pivotal Cohort data in early Q4 2026, followed by a potential De Novo marketing application in post-GLP-1 weight maintenance in late Q4 2026, with one-year Pivotal Cohort data following in Q1 2027.
The company has also been building out commercial infrastructure ahead of a possible launch, including the recent appointment of a senior market access executive with reimbursement experience from another procedural therapy company.
Beyond Revita: the Rejuva gene therapy platform
Fractyl’s second pipeline asset, Rejuva, is designed to reprogram pancreatic islet cells to durably produce metabolic hormones, aiming at long-term remission of type 2 diabetes and obesity through gene therapy rather than a procedural intervention.
The lead candidate, RJVA-001, received clinical trial authorization in the Netherlands and ethics committee approval in Australia this year, and Fractyl expects first-in-human dosing and preliminary data in the second half of 2026.
Metabolic health is one of the most consistent predictors of healthy aging, and the rapid rise of GLP-1 drugs has already reshaped how the field thinks about weight management. But a therapy people must take indefinitely to sustain its benefit is a different proposition, clinically and financially, from one that could offer a durable, one-time correction.
If procedural or gene therapy approaches like Revita and Rejuva can lock in metabolic improvements without lifelong pharmacological dependence, they represent a meaningfully different model for how metabolic disease, a major driver of accelerated aging and chronic illness, gets treated over a lifespan rather than a single treatment cycle.
